Clinical Trials and Drug Promotion: Selective Reporting of Study 329

From The Embassy of Good Science
Revision as of 13:56, 2 September 2021 by 0000-0003-3048-2023 (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Cases

Clinical Trials and Drug Promotion: Selective Reporting of Study 329

What is this about?

This article describes ethical issues regarding the Study 329. The Study wanted to determine the efficacy and safety of imipramine and paroxetine in the treatment of adolescents with major depression. However, it did not comply with the study protocol and ignored important safety problems, which led to some harmful effects.

For whom is this important?

Other information

Cookies help us deliver our services. By using our services, you agree to our use of cookies.
5.1.6